Page 1

ImmuPharma Interim Results for the 6months ended 30 June 2021 Released 29.09.2021 RNS Number : 2838N Immupharma PLC 29 September 2021 RNS : RELEASE | 29 SEPTEMBER 2021 ImmuPharma PLC ( " ImmuPharma " or the " Company " ) INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021 ImmuPharma PLC ( LSE : IMM ) , ( Euronext Growth Brussels : ALIMM ) ( " ImmuPharma " or the " Company " ) , the specialist drug discovery and development company , is pleased to announce its interim results for the six months ended 30 June 2021 ( the " Period " ) . Key Highlights ( including post Period review ) Financials • Financial performance in line with expectations over the Period o Cash balance of £ 4.2m as at 30 June 2021 ( 31 December 2020 : £ 5.9m ) o Loss for the period of £ 3.7m ( 30 June 2020 : £ 3m ) o Research and development expenses of £ 1.3m ( 30 June 2020 : £ 0.9m ) ○ Administrative expenses of £ 1.5m ( 30 June 2020 : £ 1m ) o Derivative financial asset of £ 0.2m as at 30 June 2021 ( 31 December 2020 : £ 1.2m ) o Incanthera financial asset of £ 1.2m ( £ 1.8m at 31 December 2020 ) and warrants financial asset of £ 0.2m ( £ 0.6m at 31 December 2020 ) o Convertible loan notes of £ 0.7m ( £ 0.6m at 31 December 2020 ) ○ Share based expense of £ 0.3m ( 30 June 2020 : £ 1m ) ○ Basic and diluted loss per share of 1.46p ( 30 June 2020 : 1.69p ) ' Autoimmunity ' : P140 Lupuzor ™ ( P140 ) - now entering a pharmacokinetic ( " PK " ) study prior to the optimized Phase 3 study in lupus in conjunction with its licensing partner , Avion Pharmaceuticals . о P140 for Chronic Inflammatory Demyelinating Polyneuropathy ( " CIDP " ) a neurological disorder targeting the body's nerves . Active preparation for a phase 2/3 clinical study has now been initiated . Potential further clinical applications based on further preclinical investigation include asthma , Sjogrens syndrome , renal inflammation in diabetes and periodontitis . ' Anti - infection ' о BioAMB , a novel peptide - based drug that offers a potential improvement on the limiting side effects of current Amphotericin - B ( " AMB " ) formulations . AMB is one of a last line of agents against serious and life - threatening fungal infections caused by the aspergillus family of fungi . о Board changes BioCin , a novel peptide - based drug based on an existing potent antibacterial used in high medical need cases . BioCin has the potential to offer improved safety and / or administration benefits . • New Board established : о Tim McCarthy appointed as Chief Executive Officer ( " CEO " ) ○ Dr Tim Franklin appointed as Chief Operating Officer ( " COO " ) . ○ Non Executive Directors ( " NED " ) appointed - Dr Sanjeev Pandya & Lisa Baderoon .